MX2022009332A - Derivados de indazol como agonistas parciales de los receptores cannabinoides. - Google Patents
Derivados de indazol como agonistas parciales de los receptores cannabinoides.Info
- Publication number
- MX2022009332A MX2022009332A MX2022009332A MX2022009332A MX2022009332A MX 2022009332 A MX2022009332 A MX 2022009332A MX 2022009332 A MX2022009332 A MX 2022009332A MX 2022009332 A MX2022009332 A MX 2022009332A MX 2022009332 A MX2022009332 A MX 2022009332A
- Authority
- MX
- Mexico
- Prior art keywords
- partial agonists
- disorders
- receptor partial
- indazole derivatives
- cannabanoid receptor
- Prior art date
Links
- 239000004031 partial agonist Substances 0.000 title abstract 2
- 125000003453 indazolyl group Chemical class N1N=C(C2=C1C=CC=C2)* 0.000 title 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 2
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 abstract 1
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000026594 alcoholic fatty liver disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente divulgación incluye agonistas parciales periféricos de uno o más receptores CB, incluyendo la modulación de CB1, con y sin selectividad CB2. Los compuestos de la presente divulgación pueden ser útiles en el tratamiento de enfermedades y trastornos mediados por una vía de señalización CB, incluyendo, pero sin limitarse al dolor, trastornos gastrointestinales, trastornos metabólicos y trastornos hepáticos, como esteatohepatitis alcohólica o esteatohepatitis no alcohólica (EHNA).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062967713P | 2020-01-30 | 2020-01-30 | |
| PCT/US2021/015815 WO2021155227A1 (en) | 2020-01-30 | 2021-01-29 | Indazole derivatives as cannabanoid receptor partial agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022009332A true MX2022009332A (es) | 2022-10-21 |
Family
ID=77079196
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022009332A MX2022009332A (es) | 2020-01-30 | 2021-01-29 | Derivados de indazol como agonistas parciales de los receptores cannabinoides. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230339863A1 (es) |
| EP (1) | EP4097088A4 (es) |
| JP (2) | JP2023513017A (es) |
| CN (1) | CN115348958A (es) |
| AU (1) | AU2021213804A1 (es) |
| CA (1) | CA3164719A1 (es) |
| MX (1) | MX2022009332A (es) |
| WO (1) | WO2021155227A1 (es) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0705656D0 (en) * | 2007-03-23 | 2007-05-02 | Addex Pharmaceuticals Sa | Novel compounds E1 |
| WO2009106980A2 (en) * | 2008-02-29 | 2009-09-03 | Pfizer Inc. | Indazole derivatives |
| EP2265335A1 (en) * | 2008-02-29 | 2010-12-29 | Pfizer Inc. | Indazole derivatives |
| WO2010028192A1 (en) * | 2008-09-03 | 2010-03-11 | Repligen Corporation | Compositions including 6-aminohexanoic acid derivatives as hdac inhibitors |
| WO2014167530A1 (en) * | 2013-04-11 | 2014-10-16 | Bowden Matthew James | Cannabinoid compounds |
-
2021
- 2021-01-29 WO PCT/US2021/015815 patent/WO2021155227A1/en unknown
- 2021-01-29 JP JP2022546007A patent/JP2023513017A/ja active Pending
- 2021-01-29 AU AU2021213804A patent/AU2021213804A1/en active Pending
- 2021-01-29 CA CA3164719A patent/CA3164719A1/en active Pending
- 2021-01-29 CN CN202180011700.9A patent/CN115348958A/zh active Pending
- 2021-01-29 EP EP21747795.9A patent/EP4097088A4/en active Pending
- 2021-01-29 MX MX2022009332A patent/MX2022009332A/es unknown
- 2021-01-29 US US17/796,419 patent/US20230339863A1/en active Pending
-
2024
- 2024-01-26 JP JP2024010021A patent/JP2024028642A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021213804A1 (en) | 2022-08-18 |
| JP2023513017A (ja) | 2023-03-30 |
| CN115348958A (zh) | 2022-11-15 |
| EP4097088A4 (en) | 2024-01-24 |
| US20230339863A1 (en) | 2023-10-26 |
| EP4097088A1 (en) | 2022-12-07 |
| CA3164719A1 (en) | 2021-08-05 |
| WO2021155227A1 (en) | 2021-08-05 |
| JP2024028642A (ja) | 2024-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009012000A (es) | Derivados de pirazol heteroarilo sustituidos utiles para el tratamiento de trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis. | |
| WO2010008831A3 (en) | Compounds and methods for modulating g protein-coupled receptors | |
| MX2011006006A (es) | Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos. | |
| WO2008061109A3 (en) | Indazole derivatives useful as melanin concentrating receptor ligands | |
| TN2011000437A1 (en) | Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof | |
| MX2021015427A (es) | Vesiculas extracelulares microbianas procesadas. | |
| MX2009009581A (es) | Indazoles usados para tratar trastornos mediados por el receptor de estrogenos beta. | |
| EA023861B3 (ru) | Производные пирролидин карбоновой кислоты как агонисты сопряженного с g-белком рецептора 43 (gpr43), фармацевтическая композиция и методы их использования при лечении метаболических нарушений | |
| WO2008012227A8 (en) | Pyrazoles as glucokinase activators | |
| HK1149764A1 (es) | ||
| TNSN08373A1 (en) | Azolopyrimidines as inhibitors of cannabinoid 1 activity | |
| GEP20146125B (en) | Aminopyrimidines as syk inhibitors | |
| WO2008070692A8 (en) | Bicyclic compounds and use as antidiabetics | |
| MX2009006339A (es) | Compuestos y composiciones como inhibidores de actividad de receptor 1 de cannabinoide. | |
| WO2005070072A3 (en) | Reciprocal regulation of inflammation and lipid metabolism by liver x receptors | |
| EA201170601A1 (ru) | Модуляторы регулятора трансмембранной проводимости при муковисцидозе | |
| TR201819564T4 (tr) | Cmt ve ilgili bozuklukların tedavisi için yeni terapötik yaklaşımlar. | |
| WO2009106980A3 (en) | Indazole derivatives | |
| NZ746950A (en) | Heterocyclic gpr119 agonist compounds | |
| AU2017258781A1 (en) | Di-substituted pyrazole compounds for the treatment of diseases | |
| CA2912921C (en) | Pyrazole compounds as modulators of fshr and uses thereof | |
| TN2012000531A1 (en) | Substituted heterocyclyl benzyl pyrazoles, and use thereof | |
| SG10201806854XA (en) | Compositions comprising 15-ohepa and methods of using the same | |
| GEP20146099B (en) | Fused imidazole carboxamides as trpv3 modulators | |
| MX2023008330A (es) | Agonistas del receptor dual gip/glp-1 de molécula pequeña, composiciones farmacéuticas y preparación de las mismas para usarse en el tratamiento de trastornos metabólicos y hepáticos. |